{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:53:31Z","timestamp":1777442011266,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI JP19K16832"],"award-info":[{"award-number":["KAKENHI JP19K16832"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI JP22K08475"],"award-info":[{"award-number":["KAKENHI JP22K08475"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI JP23K07264"],"award-info":[{"award-number":["KAKENHI JP23K07264"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a malignancy characterized by differentiation arrest of hematopoietic precursor cells. Differentiation therapy is effective for patients with acute promyelocytic leukemia; however, only a few effective differentiation therapies have been established for patients with other AML subtypes. In this study, seven benzimidazole anthelmintics were examined to determine the effects of differentiation on AML cells. The expression of monocyte markers (CD11b and CD14) was elevated after treatment with most benzimidazole anthelmintics. Among these drugs, parbendazole (PBZ) induced AML cell differentiation at low concentration. PBZ induced the monocyte marker expression, <jats:italic>KLF4\/DPYSL2A<\/jats:italic> gene expression, and apoptosis for 21 AML cell lines with various subtypes and a primary AML sample. Finally, an in vivo analysis using an AML patient-derived xenograft mouse model showed a significant decrease in the chimerism level and prolonged survival in PBZ-treated mice. These findings could lead to a more effective differentiation therapy for AML.<\/jats:p>","DOI":"10.1038\/s42003-024-05811-8","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:14:53Z","timestamp":1706105693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-006X","authenticated-orcid":false,"given":"Hidemasa","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Inagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinju","family":"Iyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutarou","family":"Harata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Higashitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Noura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-4500","authenticated-orcid":false,"given":"Takashi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-6520","authenticated-orcid":false,"given":"Junko","family":"Takita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsutoshi","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souichi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"5811_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc989","volume":"3","author":"DG Tenen","year":"2003","unstructured":"Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89\u2013101 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"5811_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"ME Huang","year":"1988","unstructured":"Huang, M. E. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567\u2013572 (1988).","journal-title":"Blood"},{"key":"5811_CR3","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu, C. et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94, 3315\u20133324 (1999).","journal-title":"Blood"},{"key":"5811_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","volume":"130","author":"MD Amatangelo","year":"2017","unstructured":"Amatangelo, M. D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130, 732\u2013741 (2017).","journal-title":"Blood"},{"key":"5811_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1369\/00221554211062499","volume":"70","author":"RJ Molenaar","year":"2022","unstructured":"Molenaar, R. J. & Wilmink, J. W. IDH1\/2 mutations in cancer stem cells and their implications for differentiation therapy. J Histochem Cytochem 70, 83\u201397 (2022).","journal-title":"J Histochem Cytochem"},{"key":"5811_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gene.2017.02.025","volume":"611","author":"AM Ghaleb","year":"2017","unstructured":"Ghaleb, A. M. & Yang, V. W. Kr\u00fcppel-like factor 4 (KLF4): What we currently know. Gene 611, 27\u201337 (2017).","journal-title":"Gene"},{"key":"5811_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1172\/JCI64745","volume":"123","author":"K Faber","year":"2013","unstructured":"Faber, K. et al. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR\u03b3 signaling. J. Clin. Invest. 123, 299\u2013314 (2013).","journal-title":"J. Clin. Invest."},{"key":"5811_CR8","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1038\/sj.emboj.7601824","volume":"26","author":"MW Feinberg","year":"2007","unstructured":"Feinberg, M. W. et al. The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO. J. 26, 4138\u20134148 (2007).","journal-title":"EMBO. J."},{"key":"5811_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76951-0","volume":"10","author":"M Noura","year":"2020","unstructured":"Noura, M. et al. Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells. Sci. Rep. 10, 20245 (2020).","journal-title":"Sci. Rep."},{"key":"5811_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.17557","volume":"194","author":"M Noura","year":"2021","unstructured":"Noura, M. et al. Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kr\u00fcppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis. Br. J. Haematol. 194, 598\u2013603 (2021).","journal-title":"Br. J. Haematol."},{"key":"5811_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00001432-200212000-00008","volume":"15","author":"J Horton","year":"2002","unstructured":"Horton, J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr. Opin. Infect. Dis. 15, 599\u2013608 (2002).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"5811_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.canlet.2021.08.009","volume":"520","author":"H Yi","year":"2021","unstructured":"Yi, H. et al. Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Lett. 520, 307\u2013320 (2021).","journal-title":"Cancer Lett."},{"key":"5811_CR13","doi-asserted-by":"publisher","first-page":"112029","DOI":"10.1016\/j.biopha.2021.112029","volume":"142","author":"S Saber","year":"2021","unstructured":"Saber, S. et al. Albendazole-loaded cubosomes interrupt the ERK1\/2-HIF-1\u03b1-p300\/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression. Biomed. Pharmacother. 142, 112029 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"5811_CR14","doi-asserted-by":"publisher","first-page":"594141","DOI":"10.3389\/fonc.2020.594141","volume":"10","author":"I Chung","year":"2021","unstructured":"Chung, I. et al. Unbiased phenotype-based screen identifies therapeutic agents selective for metastatic prostate cancer. Front. Oncol. 10, 594141 (2021).","journal-title":"Front. Oncol."},{"key":"5811_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91629-x","volume":"11","author":"Y KalantarMotamedi","year":"2021","unstructured":"KalantarMotamedi, Y. et al. Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells. Sci. Rep. 11, 12537 (2021).","journal-title":"Sci. Rep."},{"key":"5811_CR16","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","volume":"115","author":"PA Spagnuolo","year":"2010","unstructured":"Spagnuolo, P. A. et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115, 4824\u20134833 (2010).","journal-title":"Blood"},{"key":"5811_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53290-3","volume":"9","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index. Sci. Rep. 9, 16775 (2019).","journal-title":"Sci. Rep."},{"key":"5811_CR18","doi-asserted-by":"publisher","first-page":"670804","DOI":"10.3389\/fonc.2021.670804","volume":"11","author":"YQ Li","year":"2021","unstructured":"Li, Y. Q. et al. Repositioning of antiparasitic drugs for tumor treatment. Front. Oncol. 11, 670804 (2021).","journal-title":"Front. Oncol."},{"key":"5811_CR19","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/cancers11122042","volume":"11","author":"R Florio","year":"2019","unstructured":"Florio, R. et al. The benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer. Cancers (Basel) 11, 2042 (2019).","journal-title":"Cancers (Basel)"},{"key":"5811_CR20","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.4110\/in.2020.20.e29","volume":"20","author":"DS Son","year":"2020","unstructured":"Son, D. S., Lee, E. S. & Adunyah, S. E. The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Netw. 20, e29 (2020).","journal-title":"Immune Netw."},{"key":"5811_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11508-2","volume":"7","author":"YC Lo","year":"2017","unstructured":"Lo, Y. C. et al. Computational cell cycle profiling of cancer cells for prioritizing FDA-approved drugs with repurposing potential. Sci. Rep. 7, 11261 (2017).","journal-title":"Sci. Rep."},{"key":"5811_CR22","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.apsb.2021.12.005","volume":"12","author":"D Liang","year":"2022","unstructured":"Liang, D. et al. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning. Acta Pharm. Sin. B 12, 2429\u20132442 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"5811_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1042\/bst0150059","volume":"15","author":"K Gull","year":"1987","unstructured":"Gull, K., Dawson, P. J., Davis, C. & Byard, E. H. Microtubules as target organelles for benzimidazole anthelmintic chemotherapy. Biochem. Soc. Trans. 15, 59\u201360 (1987).","journal-title":"Biochem. Soc. Trans."},{"key":"5811_CR24","doi-asserted-by":"publisher","first-page":"W652","DOI":"10.1093\/nar\/gkq367","volume":"38","author":"M Hattori","year":"2010","unstructured":"Hattori, M., Tanaka, N., Kanehisa, M. & Goto, S. SIMCOMP\/SUBCOMP: chemical structure search servers for network analyses. Nucleic Acids Res. 38, W652\u2013W656 (2010).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-05811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-05811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-05811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:21:42Z","timestamp":1706106102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-05811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-05811-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}